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Background: Ataluren acts at the level of the ribosome to enable readthrough
of premature termination codons and production of full-length CFTR protein in
individuals with CF carrying nonsense mutations (nmCF).
Methods: This Phase 3, open-label extension study enrolled patients who had com-
pleted the preceding 48-wk randomized double-blind study (Study 009). Patients
were 6 yrs of age with nmCF and received daily TID ataluren 10, 10, 20mg/kg
for 96 wks. Safety and efﬁcacy endpoints, including adverse event rates, laboratory
testing, spirometry, and pulmonary exacerbation rates were determined.
Results: The study enrolled 191 patients, of which 148 patients have now completed
at least 48 wks of ataluren. Current data show that patients who completed 48 wks
had a mean relative change from baseline in %-pred FEV1 of −0.3%, suggesting
that the effect of ataluren is sustained over the duration of the study. Those patients
who received ataluren in Study 009 (n = 95) had a mean relative change from
baseline in %-pred FEV1 of −1.0%; those patients who received placebo in Study
009 (n = 96) had a mean relative change from baseline in %-pred FEV1 of +0.4%.
The Study 009 placebo group had previously demonstrated a mean relative change
from baseline in %-pred FEV1 of −5.5%. No increases in frequency of previously
reported adverse events or noteworthy numbers of new adverse events have been
seen in the open-label extension study.
Conclusion: Positive trends in lung function in this open-label extension study of
ataluren suggest that ataluren’s effect is sustained over time. Ataluren remains well
tolerated, and is a promising investigational new drug targeting the underlying cause
of nmCF.
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Objectives: Ivacaftor is the ﬁrst licensed medication to target the basic CFTR defect
in CF patients. Although outcomes in clinical trials have been impressive, trial use
has been restricted to patients with FEV1 >40% predicted. We aimed to assess the
response to ivacaftor in patients carrying the G551D gene mutation with severe CF
(FEV1 <40% predicted), to whom it had been supplied on a compassionate basis prior
to regulatory approval.
Methods: All 9 CF centres with severe CF patients on compassionate-use ivacaftor
in the UK and Ireland took part. Clinical data were collected for 1 year prior and a
minimum of 3 months post ivacaftor commencement. CTs within 2 years of ivacaftor
start were scored by an independent radiologist.
Results: 16 patients (7 male), median age 22 years, received ivacaftor for a median
185 days. Mean±sd (%pred) FEV1 at baseline was 0.87±0.27 L (23.6%). FEV1
improved by a median 0.13 L to 1.05±0.42 L (28.4%), p = 0.025. Mean weight improved
from 52.6 to 55.2 kg, median improvement 1.2 kg, p = 0.038. There was no signiﬁcant
correlation between any pre-treatment CT feature and measures of clinical response.
All patients were alive at follow-up. There were no recorded adverse drug reactions.
2 patients were able to stop continuous oxygen.
Conclusions: Patients with severe CF exhibit clinically relevant responses to ivacaftor,
similar to those reported in trials. There was a relative improvement of 18% in
baseline spirometry following ivacaftor and a signiﬁcant increase in weight. The clinical
response to ivacaftor appears to be independent of the extent and severity of the
underlying disease. This study constitutes the ﬁrst report of outcomes in such patients.
